Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 19, 2016
Reporting Period: Specific event date of August 19, 2016.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding regulatory events and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing reports two significant regulatory approvals from the U.S. Food and Drug Administration (FDA) for the Company's product Trokendi XR:
- Tentative Approval: Granted for a Supplemental New Drug Application (sNDA) to expand the label for Trokendi XR to include prophylaxis of migraine headache in adults.
- Final Approval: Granted to expand the label for Trokendi XR for monotherapy treatment of partial onset seizures to include adults and pediatric patients 6 years and older (previously restricted to patients 10 years and older).
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) announcing the FDA actions. No specific financial guidance or forward-looking projections were included in the text of this 8-K.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard regulatory process implied by the "tentative" nature of the migraine approval, which typically requires a final review before full marketing approval.
Investor Verification Checklist
- Verify the status of the "tentative" FDA approval for migraine prophylaxis and the timeline for final approval.
- Confirm the commercial launch strategy for the expanded pediatric indication (ages 6+) for partial onset seizures.
- Review the full text of the press release (Exhibit 99.1) for any additional details on market potential or competitive landscape.
- Check subsequent filings for financial impact projections related to these label expansions.